Unlock instant, AI-driven research and patent intelligence for your innovation.

MicroRNA (Ribonucleic Acid) relevant to diabetes mellitus endothelial progenitor cell paralysis and application thereof

A technology of endothelial progenitor cells and diabetes, applied in the field of microRNA and its application, can solve the problem of decreased expression level of miRNA, and achieve the effect of perfecting the formation mechanism

Inactive Publication Date: 2013-07-10
XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Recent studies have found that there is a decrease in the expression level of related miRNAs in the serum of diabetic patients [14] , but there are no relevant reports on miRNAs related to EPC functional impairment in diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • MicroRNA (Ribonucleic Acid) relevant to diabetes mellitus endothelial progenitor cell paralysis and application thereof
  • MicroRNA (Ribonucleic Acid) relevant to diabetes mellitus endothelial progenitor cell paralysis and application thereof
  • MicroRNA (Ribonucleic Acid) relevant to diabetes mellitus endothelial progenitor cell paralysis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1. Screening method for microRNA related to functional impairment of diabetic endothelial progenitor cells

[0040] Step 1. The peripheral blood of age- and sex-matched diabetic patients and non-diabetic patients was collected in vitro, EPCs were sorted by magnetic beads, and the phenotype and purity were identified.

[0041] 1. Research subjects: This study was divided into a diabetic group and a non-diabetic group according to age and gender matching. Among them, there were 15 diabetic patients and 15 non-diabetic patients. According to the principle of informed consent, 15ml of peripheral blood was drawn from each patient. Inclusion criteria for diabetic patients (WHO1999 diagnostic criteria): ①diabetic symptoms and plasma glucose level at any time >11.1mmol / L (200mg / dl) or ②fasting plasma glucose (FPG) level ≥7.0mmol / L (126mg / dl) or ③OGTT (Oral glucose tolerance test), 2-hour blood glucose level ≥ 11.1 mmol / L (200 mg / dl). Serious infection, severe liver and...

Embodiment 2

[0067] Example 2. In vitro study of microRNAs related to functional impairment of diabetic endothelial progenitor cells

[0068] The effects of downregulation of miR-21, miR-27a, miR-27b, miR-126, and miR-130a on bone marrow-derived endothelial progenitor cells (EPC), including the effects on EPC clone formation and EPC apoptosis, were studied respectively. effect.

[0069] Step 1, miR-21, miR-27a, miR-27b, miR-126, miR-130a down-regulation design.

[0070] 1. The inhibitor used to down-regulate miRNA expression was purchased from Ambion Company, the product number is AM17000, and the negative control is a nonsense inhibitor, the product number is AM17010.

[0071] 2. Transfect the primary cell line.

[0072] ①Digest the primary cells in the logarithmic growth phase with trypsin, and the cell density is 5×10 6 / L time; re-inoculate at 10cm 2 Cell culture dish, 37°C, 5% CO 2 Cultured in an incubator. ② Transfect when the cell confluency reaches 50%-60%. Aspirate the medi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a microRNA (Ribonucleic Acid) relevant to diabetes mellitus endothelial progenitor cell paralysis and application thereof to the change of the angiogenesis capacity of an endothelial progenitor cell and the preparation of a medicament for preventing and treating the diabetes mellitus atherosclerosis disease. The microRNA is hsa-miR-21, hsa-miR-27a, hsa-miR-27b, hsa-miR-126and hsa-miR-130a. Due to the adoption of the invention, the forming mechanism of the diabetes mellitus atherosclerosis is completed, and a novel treating target spot for preventing and treating the diabetes mellitus atherosclerosis is developed.

Description

technical field [0001] The present invention relates to the field of treatment of diabetic atherosclerotic disease, and more particularly, to microRNA related to functional impairment of diabetic endothelial progenitor cells and its application. Background technique [0002] Coronary atherosclerotic heart disease is still the leading cause of death in Western society. Endothelial damage is the first step in the atherosclerotic process [1，2] . The damaged endothelial monolayer can be regenerated by differentiation of bone marrow-derived endothelial progenitor cells (EPCs) into endothelial cells. EPC limits the development of atherosclerosis by enhancing vascular re-endothelialization [3] Therefore, EPC functional impairment is one of the main links in the initiation of atherosclerosis [4] . It is well known that diabetes can promote the occurrence and development of coronary atherosclerosis, and cardiovascular complications are the main cause of death in diabetic patient...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/113A61K48/00A61P3/10A61P9/10
Inventor 王长谦孟舒张小平
Owner XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE